Pitavastatin and Sofosbuvir/Velpatasvir Interaction
Drug interaction information between Pitavastatin and Sofosbuvir/Velpatasvir.
Pitavastatin and Sofosbuvir/Velpatasvir have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Pitavastatin and Sofosbuvir/Velpatasvir. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
The hepatitis C medicine increases the amount of pitavastatin that stays in your blood. This happens because the medicine interferes with how your body normally processes and removes the cholesterol drug.
FDA Label Information
pitavastatin ↑ pitavastatin Coadministration with VOSEVI may increase the concentration of pitavastatin and is not recommended, due to an increased risk of myopathy, including rhabdomyolysis.
Pitavastatin Also Interacts With
- Cyclosporine major
- Erythromycin major
- Rifampin major
- Colchicine moderate
- Gemfibrozil moderate
Sofosbuvir/Velpatasvir Also Interacts With
- Rifampin major
- Rosuvastatin major
- Rosuvastatin/Ezetimibe major
- Pravastatin moderate
- Methotrexate moderate
Frequently Asked Questions
What SPL severity band is on file for Pitavastatin + Sofosbuvir/Velpatasvir?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Sofosbuvir/Velpatasvir has 33 labeled pairs on file vs Pitavastatin's 9. In the moderate band specifically: Pitavastatin has 4 (also Colchicine, Gemfibrozil, Niacin); Sofosbuvir/Velpatasvir has 10 (also Pravastatin, Methotrexate, Cyclosporine, Carbamazepine).
What mechanism field is on file for Pitavastatin and Sofosbuvir/Velpatasvir?
The hepatitis C medicine increases the amount of pitavastatin that stays in your blood. This happens because the medicine interferes with how your body normally processes and removes the cholesterol drug.
Sofosbuvir/Velpatasvir's labeled portfolio outnumbers Pitavastatin
SPL source-record counts only. This page's band is moderate · classes on file: Pitavastatin (HMG-CoA Reductase Inhibitor (Statin)); Sofosbuvir/Velpatasvir (NS5B/NS5A Inhibitor (HCV)).
3 major · 4 moderate · 2 minor · 9 total
- Other moderate peers for Pitavastatin
- Colchicine
- Gemfibrozil
- Niacin
3 major · 10 moderate · 20 minor · 33 total
- Other moderate peers for Sofosbuvir/Velpatasvir
- Pravastatin
- Methotrexate
- Cyclosporine
- Carbamazepine
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.